An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 24 Months (<2 Years) of Age With Epilepsy

Trial Profile

An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 24 Months (<2 Years) of Age With Epilepsy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 11 Sep 2017 Planned End Date changed from 1 Mar 2019 to 1 Sep 2018.
    • 11 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top